Search Results - "Breet, N J"

Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel by BOUMAN, H. J., PARLAK, E., VAN WERKUM, J. W., BREET, N. J., TEN CATE, H., HACKENG, C. M., TEN BERG, J. M., TAUBERT, D.

“…Background: Multiple platelet function tests claim to be P2Y12‐pathway specific and capable of capturing the biological activity of clopidogrel…”
Get full text

High on‐aspirin platelet reactivity as measured with aggregation‐based, cyclooxygenase‐1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events by BREET, N. J., VAN WERKUM, J. W., BOUMAN, H. J., KELDER, J. C., TEN BERG, J. M., HACKENG, C. M.

“…Background: High on‐aspirin platelet reactivity (HAPR) is associated with atherothrombotic events following percutaneous coronary intervention (PCI). The aim…”
Get full text

The effect of correcting VerifyNow P2Y12 assay results for hematocrit in patients undergoing percutaneous coronary interventions by Janssen, P. W. A., Bergmeijer, T. O., Godschalk, T. C., Le, T. T. D., Breet, N. J., Kelder, J. C., Hackeng, C.M., Ten Berg, J. M.

“…Essentials Platelet reactivity is correlated with thrombotic risk after percutaneous coronary intervention (PCI). Hematocrit (HCT) is associated with platelet…”
Get full text

Variability in on-treatment platelet reactivity explained by CYP2C192 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting by Bouman, Heleen J, Harmsze, Ankie M, van Werkum, Jochem W, Breet, Nicoline J, Bergmeijer, Th O, Ten Cate, Hugo, Hackeng, Christian M, Deneer, Vera H M, Ten Berg, Jurriën M

“…An inadequate response to clopidogrel is mainly attributable to the variable formation of its active metabolite. The CYP2C19*2 loss-of-function polymorphism…”
Get more information

Acute and subacute stent thrombosis after primary percutaneous coronary intervention for ST‐segment elevation myocardial infarction: incidence, predictors and clinical outcome by HEESTERMANS, A. A. C. M., VAN WERKUM, J. W., ZWART, B., VAN DER HEYDEN, J. A., KELDER, J. C., BREET, N. J., VAN'T HOF, A. W. J., DAMBRINK, J.‐H. E., KOOLEN, J. J., BRUEREN, B. R. G., ZIJLSTRA, F., TEN BERG, J. M.

“…Background: Early coronary stent thrombosis occurs most frequent after primary percutaneous coronary intervention (PCI) for ST‐segment elevation myocardial…”
Get full text

Combined influence of proton‐pump inhibitors, calcium‐channel blockers and CYP2C192 on on‐treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention by HARMSZE, A. M., VAN WERKUM, J. W., SOUVEREIN, P. C., BREET, N. J., BOUMAN, H. J., HACKENG, C. M., RUVEN, H. J. T., TEN BERG, J. M., KLUNGEL, O. H., DE BOER, A., DENEER, V. H. M.

“…Background: The carriage of CYP2C19*2 and the use of proton‐pump inhibitors (PPIs) and calcium‐channel blockers (CCBs) has been associated with the diminished…”
Get full text

Effect of gender difference on platelet reactivity by Breet, N. J., Sluman, M. A., van Berkel, M. A. J. P. J., van Werkum, J. W., Bouman, H. J., Harmsze, A. M., Kelder, J. C., Zijlstra, F., Hackeng, C. M., ten Berg, J. M.

“…Background Previous studies have suggested that women do not accrue equal therapeutic benefit from antiplatelet medication as compared with men. The…”
Get full text

A case–control study on platelet reactivity in patients with coronary stent thrombosis by BOUMAN, H. J., VAN WERKUM, J. W., BREET, N. J., TEN CATE, H., HACKENG, C. M., TEN BERG, J. M.

“…Background: The pathophysiology of stent thrombosis (ST) has evolved from the identification of single causative factors to a complex multifactorial model…”
Get full text

Do not adjust the platelet count in light transmittance aggregometry when predicting thrombotic events after percutaneous coronary intervention by BREET, N. J., VAN WERKUM, J. W., BOUMAN, H. J., KELDER, J. C., TEN BERG, J. M., HACKENG, C. M.

Get full text

High versus standard clopidogrel loading in patients undergoing carotid artery stenting prior to cardiac surgery to assess the number of microemboli detected with transcranial Doppler: results of the randomized IMPACT trial by Van Der Heyden, J, Van Werkum, J, Hackeng, C M, Kelder, J C, Breet, N J, Deneer, V H M, Ackerstaff, R G A, Tromp, S C, De Vries, J P P M, Vos, J A, Suttorp, M J, Elsenberg, E H A, Van Neerven, D, Schonewille, W J, Wolters, F, Ten Berg, J M

“…The aim of this study was to compare the effects of 300 mg or 600 mg clopidogrel loading dose, prior to carotid artery stenting (CAS) on the number of…”
Get full text

Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk? by Breet, N. J., van Donkersgoed, H. E., van Werkum, J. W., Bouman, H. J., Kelder, J. C., Zijlstra, F., Hackeng, C. M., ten Berg, J. M.

“…Background The TRITON-TIMI 38 study has identified three subgroups of patients with a higher risk of bleeding during treatment with the thienopyridine…”
Get full text

CYP2C192 and CYP2C93 alleles are associated with stent thrombosis: a case–control study by Harmsze, Ankie M., van Werkum, Jochem W., ten Berg, Jurriën M., Zwart, Bastiaan, Bouman, Heleen J., Breet, Nicoline J., van 't Hof, Arnoud W.J., Ruven, Hendrik J.T., Hackeng, Christian M., Klungel, Olaf H., de Boer, Anthonius, Deneer, Vera H.M.

“…Aims Despite treatment with clopidogrel on top of aspirin, stent thrombosis (ST) still occurs being the most serious complication after percutaneous coronary…”
Get full text

High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention by Breet, Nicoline J, van Werkum, Jochem W, Bouman, Heleen J, Kelder, Johannes C, Harmsze, Ankie M, Hackeng, Christian M, ten Berg, Jurriën M

“…High on-clopidogrel platelet reactivity (HCPR) and high on-aspirin platelet reactivity (HAPR) are associated with atherothrombotic events following coronary…”
Get more information

The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting by Breet, N J, de Jong, C, Bos, W J, van Werkum, J W, Bouman, H J, Kelder, J C, Bergmeijer, T O, Zijlstra, F, Hackeng, C M, Ten Berg, J M

“…Patients with chronic kidney disease (CKD) have an increased risk of cardiovascular disease. Previous studies have suggested that patients with CKD have less…”
Get more information

The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response by Harmsze, Ankie M, Robijns, Karen, van Werkum, Jochem W, Breet, Nicoline J, Hackeng, Christian M, Ten Berg, Jurrien M, Ruven, Hendrik J T, Klungel, Olaf H, de Boer, Anthonius, Deneer, Vera H M

“…Clopidogrel is a prodrug that has to be converted in vivo to its active metabolite by cytochrome (CYP)P450 iso-enzymes. As calcium channel blockers (CCBs) are…”
Get more information

The relationship between platelet reactivity and infarct-related artery patency in patients presenting with a ST-elevation myocardial infarction by Breet, Nicoline J, van Werkum, Jochem W, Bouman, Heleen J, Kelder, Johannes C, Hackeng, Christian M, ten Berg, Jurriën M

“…Both heightened platelet reactivity and an occluded infarct related artery (IRA) on initial angiography and at the time of primary percutaneous coronary…”
Get more information

Both peak and late aggregation are capable of identifying patients at risk for atherothrombotic events by Breet, Nicoline J, van Werkum, Jochem W, Bouman, Heleen J, Kelder, Johannes C, Ten Berg, Jurriën M, Hackeng, Christian M

Get more information